NCT05687136View on ClinicalTrials.gov

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 7, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
Interventions
PROCEDURE

Biopsy Procedure

Undergo tissue biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Peposertib

Given PO

PROCEDURE

Positron Emission Tomography

Undergo PET

DRUG

Tuvusertib

Given PO

Trial Locations (6)

10016

RECRUITING

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

11501

RECRUITING

NYU Langone Hospital - Long Island, Mineola

20892

RECRUITING

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

ACTIVE_NOT_RECRUITING

National Institutes of Health Clinical Center, Bethesda

02114

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH